BILL SHINGLETON

Director, Applications and Biology: Cell and Gene Therapy, Cytiva.

Passionate about delivering Advanced Therapeutic Medicinal Products (ATMPs) to patients. Focussed on developing technology that will enable successful translation and commercialisation.
Biological Scientist, with a background in inflammation, biology of ageing and connective tissues. Applying this research in the fields of auto-immune, degenerative diseases and oncology. Experience gained in academia at the Universities of Cambridge and Newcastle-upon-Tyne, combined with over 15 years of industrial research with Unilever R&D, GE Healthcare Life Sciences and now Cytiva. Recent roles have been supporting the Cell Therapy Industry through and the application of in-vivo imaging to enable safety, efficacy and MoA studies, and development of tools and technology for cell therapy manufacturing and cryo-preservation. Current role is focussed on Leading a global team of biologists and engineers developing technology to enable the development of equipment, consumables, software and processes for the manufacture of cell and gene therapies.